References
- Leroy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205.
- van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an american college of rheumatology/european league against rheumatism collaborative initiative: ACR/EULAR classification criteria for SSc. Arthritis Rheum. 2013; 65:2737–2747.
- Terras S, Hartenstein H, Höxtermann S, et al. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis. Int J Dermatol. 2016;55(8):882–885.
- Kreuter A, Höxtermann S, Tigges C, et al. Clonal T-cell populations are frequent in the skin and blood of patients with systemic sclerosis. Br J Dermatol. 2009;161(4):785–790.
- Gambichler T, Tigges C, Burkert B, et al. Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis. Eur J Med Res. 2010;15(1):44–46.
- Du AX, Osman M, Gniadecki R. Use of extracorporeal photopheresis in scleroderma: a review. Dermatology. 2020;236(2):105–110.
- Knobler R, Arenberger P, Arun A, et al. European dermatology forum: updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2. J Eur Acad Dermatol Venereol. 2021;35(1):27–49.
- Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 1):1–37.
- Gonzalez-Lopez L, Rocha-Muñoz AD, Olivas-Flores EM, et al. Procollagen type I and III aminoterminal propeptide levels and severity of interstitial lung disease in mexican women with progressive systemic sclerosis. Arch Bronconeumol. 2015;51(9):440–448.
- Nagy Z, Czirják L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol. 2005;23(2):165–172.
- Scheja A, Akesson A, Hørslev-Petersen K. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. Scand J Rheumatol. 1992;21(1):5–9.
- Reich S, Gambichler T, Altmeyer P, et al. Extracorporeal photopheresis in systemic sclerosis: effects on organ involvement? J Am Acad Dermatol. 2007;56(2):348–349. Feb
- Lanteri A, Sobanski V, Langlois C, et al. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev. 2014;13(9):974–980. Sep
- Sierakowski S, Bernacka K. Humoral and cellular immunity in progressive systemic sclerosis. Med Interne. 1987; 25(4):233–238.
- Swierczynska Z, Rdultowska H, Blaszczyk M, et al. Circulating immune complexes in systemic scleroderma. Immunol Commun. 1984;13(5):433–438.
- Bladon J, Taylor PC. Extracorporeal photopheresis: a focus on apoptosis and cytokines. J Dermatol Sci. 2006;43(2):85–94. Aug
- Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol. 2001;28:2454–2459.
- Zuhur F, Zuhur SS, Zuhur C, et al. Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey. Rheumatol Int. 2012;32(6):1655–1661. Jun
- Nihtyanova SI, Sari A, Harvey JC, et al. Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol. 2020;72(3):465–476. Mar
- Hefazi M, Langer KJ, Khera N, et al. Extracorporeal photopheresis improves survival in hematopoietic cell transplant patients with bronchiolitis obliterans syndrome without significantly impacting measured pulmonary functions. Biol Blood Marrow Transplant. 2018;24(9):1906–1913. Sep